|
|
| | ErythromycinAcistrate Basic information |
| Product Name: | ErythromycinAcistrate | | Synonyms: | ErythromycinAcistrate;[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] acetate | | CAS: | 96128-89-1 | | MF: | C57H105NO16 | | MW: | 1060.46 | | EINECS: | | | Product Categories: | | | Mol File: | 96128-89-1.mol |  |
| | ErythromycinAcistrate Chemical Properties |
| | ErythromycinAcistrate Usage And Synthesis |
| Description | Erythromycin acistrate is a prodrug of erythromycin with lowered liver toxicity, improved
phmacokinetics, and greatly reduced gastro-intestinal side-effects. It is indicated for
respiratory tract infections, skin infections and chlamydial urethritis. | | Originator | Orion (Finland) | | Uses | Antibacterial. | | Brand name | Erasis (Orion Pharmaceutica, Finland). |
| | ErythromycinAcistrate Preparation Products And Raw materials |
|